Peripheral Macular Endothelial Dystrophy: Clinical, Histopathologic, Genetic and Functional Characterization - 18/11/25
Résumé |
Objective |
To report a CHST6 -associated corneal endothelial dystrophy.
Design |
Prospective observational case series.
Participants |
Thirty-five individuals from seven families, including 13 affected individuals exhibiting corneal epithelial and stromal edema, peripheral posterior corneal macular opacities, and endothelial guttae, as well as 22 unaffected family members.
Methods |
Whole-exome sequencing was performed in 3 families and Sanger sequencing of CHST6 was performed in all individuals. Histological examination of Descemet membrane (DM) excised at the time of endothelial keratoplasty was performed for three probands. Serum keratan sulfate (KS) levels were measured in members of six families. Functional analysis of identified mutations was performed using CHST6 promoter containing CHST6 expression vector in human keratocytes (HK) and corneal endothelial cells (HCEnC).
Main Outcome Measures |
Clinical phenotype; genetic analysis; functional analysis of identified CHST6 mutations; serum KS levels; histologic examinations of DM.
Results |
All affected individuals demonstrated peripheral macular opacities at the level of DM. Visually significant corneal edema in affected individuals was successfully managed by endothelial keratoplasty. Genetic analysis demonstrated a rare CHST6 promoter mutation (c.-690G > C) in the homozygous state in affected individuals from three families and in the compound heterozygous state with a CHST6 coding mutation (p.R211Q, p.Y268C or p.P280L) in affected individuals from the other four families. In silico analysis predicted c.-690G > C to be a regulatory variant, located at the RNA polymerase II binding site. Functional analysis in vitro demonstrated that c.-690G > C leads to increased KS sulfation in the corneal endothelium and DM, with no change of KS sulfation in keratocytes. Histologic examination of DM from affected individuals revealed elevated levels of sulfated and non-sulfated KS in DM and endothelium, consistent with the functional analysis. Minimum changes in serum sulfated KS levels were observed in affected individuals.
Conclusions |
We suggest the name Peripheral macular endothelial dystrophy (PMED) to describe this dystrophy that is characterized by peripheral posterior corneal macular opacities and endothelial dysfunction without stromal haze or opacities. Given that both PMED and macular corneal dystrophy are associated with promoter and coding region mutations in CHST6 , we propose that they be categorized as CHST6 -associated corneal dystrophies.
Le texte complet de cet article est disponible en PDF.Plan
Vol 280
P. 154-168 - décembre 2025 Retour au numéro
Article précédent
- Delphi-Based Global Consensus on Fuchs Endothelial Corneal Dystrophy. An Endothelial Keratoplasty Learners Group Initiative
- Sanjay V. Patel, Nidhi Gupta, Maninder Bhogal, Ula V. Jurkunas, Naoki Okumura, Vito Romano, Bruce D. Allan, Keith H. Baratz, Samar K. Basak, Lamis Baydoun, Winston Chamberlain, Sunita Chaurasia, Kathryn Colby, Claus Cursiefen, Ticiano Giobellina, Mark A. Greiner, Jesper Hjortdal, Akira Kobayashi, Viridiana Kocaba, Ellen H. Koo, W. Barry Lee, Eitan Livny, John J. Males, Mario Matthaei, Jodhbir S. Mehta, Luis Mejia, Gregory Moloney, V. Vinod Mootha, Marc Muraine, Yoshinori Oie, Nicolas Cesário Pereira, Francis W. Price, Divya Srikumaran, Mark A. Terry, Peter B. Veldman, David D. Verdier, Pravin K. Vaddavalli, Roberto Pineda
- Real-World Outcomes in Eyes With Neovascular AMD Switched From Brolucizumab to Faricimab: A TRUCKEE Study Analysis
- CEREN SOYLU, GIULIA CORRADETTI, MAI ALHELALY, HANNAH KHAN, AAMIR A. AZIZ, HUMA KHAN, HAAZIQ ALI, HUMZA SULAHRIA, ARSHAD M. KHANANI, SRINIVAS SADDA
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?